Enterprise Value
1.591M
Cash
5.641M
Avg Qtr Burn
-7.432M
Short % of Float
1.40%
Insider Ownership
13.80%
Institutional Own.
44.96%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Zagociguat (CY6463) Details Dementia, Neurological disorder, Alzheimer's disease | Phase 2 Update | |
Zagociguat (CY6463) Details Cognitive Impairment Associated with Schizophrenia | Phase 1b Update | |
Praliciguat (sGC stimulator) Details Heart disease | Failed Discontinued | |
Olinciguat Details Sickle cell disease | Failed Discontinued | |
Zagociguat (CY6463) Details Rare diseases, Mitochondrial disease, Rare genetic disease | Failed Discontinued |